Stifel analyst Stephen Manaker lowered the firm’s price target on Omega Healthcare to $33 from $36 and keeps a Buy rating on the shares. The company’s Q1 results and subsequent events were "better than expected," the analyst tells investors. The firm believes it is conservative in its estimates and, as the operating environment improves, Omega could see additional repayments of deferrals. Stifel’s optimism is based on occupancy recovering, improvements in reimbursement rates, and labor costs ameliorating.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OHI: